ArticleDiscover oncology2025
Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBladder cancer (BLCA) is one of the most invasive and malignant tumors in the world, thus leading to the urgent need of an accurate and recognizable biomarker. Several previous research has shown that Transient Receptor Potential Melastatin 4 (TRPM4) plays an important role in measuring vascular fragility and endothelial function. However, the role of TRPM4 in tumor hasn't been explored.
methodsWe obtained the clinical data and gene expression profiles of The Cancer Genome Atlas (TCGA) datasets via UCSC Xena. The tumor microenvironment (TME) was also evaluated by the amount of immunomodulators. The role of TRPM4 was demonstrated using the dataset GSE130001 via the website ( http://tisch.comp-genomics.org/ ). We also validated the results of the pathway analysis through the Polymerase Chain Reaction (PCR).
resultsPatients with higher TRPM4 expression showed better prognosis. We found out that high TRPM4 tended to shape an immuno-stimulatory TME with less T cell exhaustion and lower level of immune overdrive. We demonstrated that TRPM4 could predict the molecular subtype and different therapy options in BLCA. We also found the important influence of TRPM4 in P53 pathway and TNF-a pathway. Last but not least, we developed a prognostic model centered on TRPM4 using ten machine learning algorithms, which showed excellent predictive ability.
conclusionHigh TRPM4 shapes a more immuno-stimulatory tumor microenvironment and can not only predict the immune phenotypes but also predict the clinical phenotypes in BLCA. High TRPM4 predicts better prognosis. TRPM4 is a potential biomarker in the future for identifying the immunogenicity and immune-therapy probability of BLCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.